Related Experiment Video
Updated: Aug 15, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
New treatments for smoking cessation
1Department of Psychiatry at the University of Vermont in Burlington, USA.
Abstract:
Helping cigarette smokers to permanently stop smoking is one of the most effective ways to prevent cancer. A physician's instruction to a patient to stop smoking and to offer assistance in this endeavor is an important motivator. Current guidelines state that clinicians should encourage all smokers who want to quit to use medications and should offer psychosocial therapies, as well. It has been shown that even brief clinician advice about smoking cessation increases quit rates. Five medications--bupropion, nicotine gum, nicotine inhaler, nicotine nasal spray, and nicotine patch--and one proven psychosocial therapy (behavior therapy) appear equally effective and safe; i.e., they all double quit rates and are associated with a less than 5% dropout rate due to adverse events. In 1998, approximately one third of those who attempted to quit smoking used a medication. Attending group behavior therapy to supplement medications increases quit rates but is not essential for medications to work. As there are no proven treatment-matching protocols, patients should choose the treatment(s) they believe will be most effective for them. In the future, people who continue to smoke will be individuals with severe nicotine dependence or psychiatric symptoms; thus, clinicians will increasingly be called on to provide pharmacotherapy for smoking cessation.
More Related Videos
14:21Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
06:39Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
Published on: August 28, 2017
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
Antidepressant Drugs: MAOIs and Other Agents
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation